HBP:CC - Helix Biopharma Corp. Appoints Gabrielle M Siegers as the Head of Research & Development
(TheNewswire)
Toronto, Ontario – TheNewswire – September 1,2022 – Helix BioPharma Corp . (TSX:HBP) (“Helix” or the “Company”), aclinical-stage biopharmaceutical company that is developing uniquetherapies in the field of immuno-oncology based on its proprietarytechnology platform DOS47, is pleased to announce the appointment ofDr. Gabrielle M Siegers, MA, Ph.D., as the Head of R&D based outof the Company’s lab in Edmonton.
Dr. Siegers comes to Helix from IN8bio, a US biotechcompany developing Gamma Delta T Cell immunotherapies for cancer,where she served as Senior Scientist/Gamma Delta T Cell Specialist.Prior to this, Dr. Siegers was a Research Associate with theDepartment of Experimental Oncology at the University of Albertafollowing postdoctoral studies in Dr. Lynne-Marie Postovit’slaboratory, where she studied how the tumour microenvironment impactsimmune cell function. Prior to this, Dr. Siegers was a PostdoctoralFellow in the laboratory of Dr. Paula Foster, a world-renownedcellular MRI expert at Robarts Research Institute, where she continuedresearch begun in the Translational Cell Therapy Program with Dr.Armand Keating at the Princess Margaret Hospital.
“We are delighted to welcome Dr. Gabrielle Siegers asa key addition to the team. We are confident that she will lead ourR&D team toward success and help them to make significantbreakthroughs in the field of immune oncology”, said Artur Gabor,Helix’s Chief Executive Officer.
Dr. Siegers stated,"I am delighted to join Helix in this exciting capacity, to putmy knowledge and skills toward further development of Helix’spromising new cancer therapies for patients."
Gabrielle Siegers Bio
Gabrielle M. Siegers (HBSc Guelph, MA Queen’s)obtained her PhD in Molecular Immunology at the Max Planck Institutefor Immunobiology and the University of Freiburg, Germany. Ms. Siegersreturned to Canada to conduct postdoctoral research at the PrincessMargaret Hospital, Robarts Research Institute and Western University,and then worked as a Research Associate at the University of Alberta.In 2021, she became an independent scientific consultant and thensigned on full time with IN8bio, dividing time between her home officein Edmonton and the lab in Birmingham, Alabama, USA. In August 2022,Ms. Siegers began a new role in Edmonton as Head of R&D for HelixBioPharma. She has published several original research articles,reviews and book chapters with international and cross-disciplinarycollaborators (currently 32 publications on PubMed), and she has giveninvited talks at national and international meetings in Canada, theUnited States and Germany.
Helix BioPharma Corp. is a clinical-stagebiopharmaceutical company developing unique therapies in the field ofimmune-oncology for the prevention and treatment of cancer, based onthe proprietary technology platform DOS47. Helix is listed on the TSXunder the symbol “HBP.”
For more information, please contact:
Helix BioPharma Corp.
Suite 2704, 401 Bay Street Toronto, Ontario, M5H 2Y4
Tel: 905-841-2300
Namrata Malhotra, CorporateSecretary
Forward-LookingStatements and Risks and Uncertainties
This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to DOS47, and statementsregarding expected improvements to the Company’s independence, diversification andcorporate governance and the Company’s expectations regardingstrengthening its future growth capabilities. Forward-lookingstatements can further be identified by the use of forward-lookingterminology such as “ongoing”, “estimates”, “expects”, orthe negative thereof or any other variations thereon or comparableterminology referring to future events or results, or that events orconditions “will”, “may”, “could”, or “should” occuror be achieved, or comparable terminology referring to future eventsor results.
Forward-looking statements arestatements about the future and are inherently uncertain and arenecessarily based upon a number of estimates and assumptions that arealso uncertain. Although the Company believes that the expectationsreflected in such forward- looking statements are reasonable, suchstatements involve risks and uncertainties, and undue reliance shouldnot be placed on such statements. Forward-looking statements,including financial outlooks, are intended to provide informationabout management’s current plans and expectations regarding futureoperations, including without limitation, future financingrequirements, and may not be appropriate for other purposes. Certainmaterial factors, estimates or assumptions have been applied in makingforward-looking statements in this news release.
The Company’s actual results coulddiffer materially from those anticipated in the forward-lookingstatements contained in this news release as a result of numerousknown and unknown risks and uncertainties, including withoutlimitation; the risk that the Company’s assumptions may prove to beincorrect; the risk that additional financing may not be obtainable ina timely manner, or at all, and that clinical trials may not commenceor complete within anticipated timelines or the anticipated budget ormay fail; third party suppliers of necessary services or of drugproduct and other materials may fail to perform or be unwilling orunable to supply the Company, which could cause delay or cancellationof the Company’s research and development activities; necessaryregulatory approvals may not be granted or may be withdrawn; theCompany may not be able to secure necessary strategic partner support;general economic conditions, intellectual property and insurancerisks; changes in business strategy or plans; and other risks anduncertainties referred to elsewhere in this news release, any of whichcould cause actual results to vary materially from current results orthe Company’s anticipated future results. Certain of these risks anduncertainties, and others affecting the Company, are more fullydescribed in the Company’s annual management’s discussion andanalysis for the year ended July 31, 2021 under the heading “Risksand Uncertainties” and Helix’s Annual Information Form, inparticular under the headings “Forward-looking Statements” and“Risk Factors”, and other reports filed under the Company’sprofile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information arebased on the beliefs, assumptions, opinions and expectations ofHelix’s management on the date of this new release, and the Companydoes not assume any obligation to update any forward-looking statementor information should those beliefs, assumptions, opinions orexpectations, or other circumstances change, except as required bylaw.
Copyright (c) 2022 TheNewswire - All rights reserved.